PT  - JOURNAL ARTICLE
AU  - Herminia L. Buchelli Ramirez
AU  - Celso M. Alvarez Alvarez
AU  - José J. Rodríguez Reguero
AU  - Marta M. García Clemente
AU  - Pere Casan Clará
TI  - REVERSIBLE PRE-CAPILLARY PULMONARY HYPERTENSION DUE TO DASATINIB
AID  - 10.4187/respcare.02692
DP  - 2013 Oct 22
TA  - Respiratory Care
PG  - respcare.02692
4099  - http://rc.rcjournal.com/content/early/2013/10/22/respcare.02692.short
4100  - http://rc.rcjournal.com/content/early/2013/10/22/respcare.02692.full
AB  - Pulmonary arterial hypertension (PAH) and secondary pleural effusion have been reported in association with long-term therapy with the multi tyrosine kinase inhibitor dasatinib, approved for the treatment of chronic myeloid leukemia (CML). We present the case of a 50-year-old man diagnosed with CML in August 2003, who developed PAH after more than four years of treatment with dasatinib. The complete remission of PAH following dasatinib discontinuation suggests an etiological role of the drug in its development, although the administration of sildenafil may have played a therapeutic role.